drugset / Trial / NCT01844700

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

NCT01844700

Phase 4 Terminated 14 enrolled Northwell Health
RandomizedParallel-groupOpen-label

Summary

We will conduct a 12-week, randomized open label study, comparing usual care (UC) antipsychotic treatment (aripiprazole, quetiapine, risperidone) with ziprasidone (ZIP) in children and adolescents aged 13-18 years old. Patients will have 10 days or less lifetime antipsychotic exposure and be in clinical need for antipsychotic treatment for a pediatric psychiatric disorder with FDA indication for antipsychotic use, i.e., bipolar mania, schizophrenia-spectrum disorders, and irritability associated with autistic disorder. In addition, we will also include youth fulfilling research diagnostic criteria for severe mood dysregulation (SMD). Randomization will be stratified by high vs. low genetic risk for antipsychotic-induced weight gain based on MC4R genotype and the primary outcome will be weight change from baseline to endpoint between ZIP and UC antipsychotic treatment in each of the two genotype groups. As detailed below, other metabolic and cardiac safety parameters will also be measured and compared across treatments in each of the genotype groups.

Timeline

Start
2013-07
Primary completion
2014-04
Completion
2014-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 2 mg
Comparator Aripiprazole Other / unclassified 30 mg
Comparator Quetiapine Small molecule 25 mg
Comparator Quetiapine Small molecule 800 mg
Comparator Risperidone Other / unclassified 0.1 mg
Comparator Risperidone Other / unclassified 8 mg
Comparator Ziprasidone Small molecule 20 mg
Comparator Ziprasidone Small molecule 160 mg